B-intervention	0	11	Anastrozole
O	12	15	for
O	16	26	prevention
O	27	29	of
O	30	36	breast
O	37	43	cancer
O	44	46	in
O	47	51	high
O	51	52	-
O	52	56	risk
O	57	71	postmenopausal
O	72	77	women
O	78	79	(
O	79	83	IBIS
O	83	84	-
O	84	86	II
O	86	87	)
O	87	88	:
O	89	91	an
O	92	105	international
O	105	106	,
O	107	113	double
O	113	114	-
O	114	119	blind
O	119	120	,
O	121	131	randomised
O	132	139	placebo
O	139	140	-
O	140	150	controlled
O	151	156	trial
O	156	157	.

O	158	167	Aromatase
O	168	178	inhibitors
O	179	190	effectively
O	191	198	prevent
O	199	205	breast
O	206	212	cancer
O	213	223	recurrence
O	224	227	and
O	228	239	development
O	240	242	of
O	243	246	new
O	247	260	contralateral
O	261	268	tumours
O	269	271	in
O	272	286	postmenopausal
O	287	292	women
O	292	293	.

O	294	296	We
O	297	305	assessed
O	306	309	the
O	310	318	efficacy
O	319	322	and
O	323	329	safety
O	330	332	of
O	333	336	the
O	337	346	aromatase
O	347	356	inhibitor
O	357	368	anastrozole
O	369	372	for
O	373	383	prevention
O	384	386	of
O	387	393	breast
O	394	400	cancer
O	401	403	in
O	404	418	postmenopausal
O	419	424	women
O	425	428	who
O	429	432	are
O	433	435	at
O	436	440	high
O	441	445	risk
O	446	448	of
O	449	452	the
O	453	460	disease
O	460	461	.

O	462	469	Between
O	470	473	Feb
O	474	475	2
O	475	476	,
O	477	481	2003
O	481	482	,
O	483	486	and
O	487	490	Jan
O	491	493	31
O	493	494	,
O	495	499	2012
O	499	500	,
O	501	503	we
O	504	513	recruited
O	514	528	postmenopausal
O	529	534	women
O	535	539	aged
B-age	540	542	40
I-age	542	543	-
I-age	543	545	70
I-age	546	551	years
O	552	556	from
O	557	559	18
O	560	569	countries
O	570	574	into
O	575	577	an
O	578	591	international
O	591	592	,
O	593	599	double
O	599	600	-
O	600	605	blind
O	605	606	,
O	607	617	randomised
O	618	625	placebo
O	625	626	-
O	626	636	controlled
O	637	642	trial
O	642	643	.

O	644	646	To
O	647	649	be
O	650	658	eligible
O	658	659	,
B-eligibility	660	665	women
I-eligibility	666	669	had
I-eligibility	670	672	to
I-eligibility	673	675	be
I-eligibility	676	678	at
I-eligibility	679	688	increased
I-eligibility	689	693	risk
I-eligibility	694	696	of
I-eligibility	697	703	breast
I-eligibility	704	710	cancer
O	711	712	(
O	712	718	judged
O	719	721	on
O	722	725	the
O	726	731	basis
O	732	734	of
O	735	743	specific
O	744	752	criteria
O	752	753	)
O	753	754	.

O	755	763	Eligible
O	764	769	women
O	770	774	were
O	775	783	randomly
O	784	792	assigned
O	793	794	(
O	794	795	1
O	795	796	:
O	796	797	1
O	797	798	)
O	799	801	by
O	802	809	central
O	810	818	computer
O	819	829	allocation
O	830	832	to
O	833	840	receive
O	841	842	1
O	843	845	mg
O	846	850	oral
O	851	862	anastrozole
O	863	865	or
O	866	874	matching
B-control	875	882	placebo
O	883	888	every
O	889	892	day
O	893	896	for
O	897	898	5
O	899	904	years
O	904	905	.

O	906	919	Randomisation
O	920	923	was
O	924	934	stratified
O	935	937	by
O	938	945	country
O	946	949	and
O	950	953	was
O	954	958	done
O	959	963	with
O	964	970	blocks
O	971	972	(
O	972	976	size
O	977	980	six
O	980	981	,
O	982	987	eight
O	987	988	,
O	989	991	or
O	992	995	ten
O	995	996	)
O	996	997	.

O	998	1001	All
O	1002	1007	trial
O	1008	1017	personnel
O	1017	1018	,
O	1019	1031	participants
O	1031	1032	,
O	1033	1036	and
O	1037	1047	clinicians
O	1048	1052	were
O	1053	1059	masked
O	1060	1062	to
O	1063	1072	treatment
O	1073	1083	allocation
O	1083	1084	;
O	1085	1089	only
O	1090	1093	the
O	1094	1099	trial
O	1100	1112	statistician
O	1113	1116	was
O	1117	1125	unmasked
O	1125	1126	.

O	1127	1130	The
O	1131	1138	primary
O	1139	1147	endpoint
O	1148	1151	was
B-outcome-Measure	1152	1166	histologically
I-outcome-Measure	1167	1176	confirmed
I-outcome-Measure	1177	1183	breast
I-outcome-Measure	1184	1190	cancer
O	1191	1192	(
O	1192	1200	invasive
O	1201	1208	cancers
O	1209	1211	or
O	1212	1215	non
O	1215	1216	-
O	1216	1224	invasive
O	1225	1231	ductal
O	1232	1241	carcinoma
O	1242	1244	in
O	1245	1249	situ
O	1249	1250	)
O	1250	1251	.

O	1252	1260	Analyses
O	1261	1265	were
O	1266	1270	done
O	1271	1273	by
O	1274	1283	intention
O	1284	1286	to
O	1287	1292	treat
O	1292	1293	.

O	1294	1298	This
O	1299	1304	trial
O	1305	1307	is
O	1308	1318	registered
O	1318	1319	,
O	1320	1326	number
O	1327	1341	ISRCTN31488319
O	1341	1342	.

B-intervention-participants	1343	1347	1920
O	1348	1353	women
O	1354	1358	were
O	1359	1367	randomly
O	1368	1376	assigned
O	1377	1379	to
O	1380	1387	receive
O	1388	1399	anastrozole
O	1400	1403	and
B-control-participants	1404	1408	1944
O	1409	1411	to
O	1412	1419	placebo
O	1419	1420	.

O	1421	1426	After
O	1427	1428	a
O	1429	1435	median
O	1436	1442	follow
O	1442	1443	-
O	1443	1445	up
O	1446	1448	of
O	1449	1450	5
O	1450	1451	·
O	1451	1452	0
O	1453	1458	years
O	1459	1460	(
O	1460	1463	IQR
O	1464	1465	3
O	1465	1466	·
O	1466	1467	0
O	1467	1468	-
O	1468	1469	7
O	1469	1470	·
O	1470	1471	1
O	1471	1472	)
O	1472	1473	,
B-iv-bin-abs	1474	1476	40
O	1477	1482	women
O	1483	1485	in
O	1486	1489	the
O	1490	1501	anastrozole
O	1502	1507	group
O	1508	1509	(
B-iv-bin-percent	1509	1510	2
I-iv-bin-percent	1510	1511	%
O	1511	1512	)
O	1513	1516	and
B-cv-bin-abs	1517	1519	85
O	1520	1522	in
O	1523	1526	the
O	1527	1534	placebo
O	1535	1540	group
O	1541	1542	(
B-cv-bin-percent	1542	1543	4
I-cv-bin-percent	1543	1544	%
O	1544	1545	)
O	1546	1549	had
B-outcome	1550	1559	developed
I-outcome	1560	1566	breast
I-outcome	1567	1573	cancer
O	1574	1575	(
O	1575	1581	hazard
O	1582	1587	ratio
O	1588	1589	0
O	1589	1590	·
O	1590	1592	47
O	1592	1593	,
O	1594	1596	95
O	1596	1597	%
O	1598	1600	CI
O	1601	1602	0
O	1602	1603	·
O	1603	1605	32
O	1605	1606	-
O	1606	1607	0
O	1607	1608	·
O	1608	1610	68
O	1610	1611	,
O	1612	1613	p
O	1613	1614	<
O	1614	1615	0
O	1615	1616	·
O	1616	1620	0001
O	1620	1621	)
O	1621	1622	.

O	1623	1626	The
O	1627	1636	predicted
B-outcome	1637	1647	cumulative
I-outcome	1648	1657	incidence
I-outcome	1658	1660	of
I-outcome	1661	1664	all
I-outcome	1665	1671	breast
I-outcome	1672	1679	cancers
I-outcome	1680	1685	after
I-outcome	1686	1687	7
I-outcome	1688	1693	years
O	1694	1697	was
B-cv-bin-percent	1698	1699	5
I-cv-bin-percent	1699	1700	·
I-cv-bin-percent	1700	1701	6
I-cv-bin-percent	1701	1702	%
O	1703	1705	in
O	1706	1709	the
O	1710	1717	placebo
O	1718	1723	group
O	1724	1727	and
B-iv-bin-percent	1728	1729	2
I-iv-bin-percent	1729	1730	·
I-iv-bin-percent	1730	1731	8
I-iv-bin-percent	1731	1732	%
O	1733	1735	in
O	1736	1739	the
O	1740	1751	anastrozole
O	1752	1757	group
O	1757	1758	.

B-iv-bin-abs	1759	1761	18
B-outcome	1762	1768	deaths
O	1769	1773	were
O	1774	1782	reported
O	1783	1785	in
O	1786	1789	the
O	1790	1801	anastrozole
O	1802	1807	group
O	1808	1811	and
B-cv-bin-abs	1812	1814	17
O	1815	1817	in
O	1818	1821	the
O	1822	1829	placebo
O	1830	1835	group
O	1835	1836	,
O	1837	1840	and
O	1841	1843	no
O	1844	1852	specific
O	1853	1859	causes
O	1860	1864	were
O	1865	1869	more
O	1870	1876	common
O	1877	1879	in
O	1880	1883	one
O	1884	1889	group
O	1890	1894	than
O	1895	1898	the
O	1899	1904	other
O	1905	1906	(
O	1906	1907	p
O	1907	1908	=
O	1908	1909	0
O	1909	1910	·
O	1910	1913	836
O	1913	1914	)
O	1914	1915	.

O	1916	1927	Anastrozole
O	1928	1939	effectively
O	1940	1947	reduces
B-outcome	1948	1957	incidence
I-outcome	1958	1960	of
I-outcome	1961	1967	breast
I-outcome	1968	1974	cancer
O	1975	1977	in
O	1978	1982	high
O	1982	1983	-
O	1983	1987	risk
O	1988	2002	postmenopausal
O	2003	2008	women
O	2008	2009	.

O	2010	2014	This
O	2015	2022	finding
O	2022	2023	,
O	2024	2029	along
O	2030	2034	with
O	2035	2038	the
O	2039	2043	fact
O	2044	2048	that
O	2049	2053	most
O	2054	2056	of
O	2057	2060	the
O	2061	2065	side
O	2065	2066	-
O	2066	2073	effects
O	2074	2084	associated
O	2085	2089	with
O	2090	2099	oestrogen
O	2100	2111	deprivation
O	2112	2116	were
O	2117	2120	not
O	2121	2133	attributable
O	2134	2136	to
O	2137	2146	treatment
O	2146	2147	,
O	2148	2156	provides
O	2157	2164	support
O	2165	2168	for
O	2169	2172	the
O	2173	2176	use
O	2177	2179	of
O	2180	2191	anastrozole
O	2192	2194	in
O	2195	2209	postmenopausal
O	2210	2215	women
O	2216	2218	at
O	2219	2223	high
O	2224	2228	risk
O	2229	2231	of
O	2232	2238	breast
O	2239	2245	cancer
O	2245	2246	.

O	2247	2253	Cancer
O	2254	2262	Research
O	2263	2265	UK
O	2265	2266	,
O	2267	2270	the
O	2271	2279	National
O	2280	2286	Health
O	2287	2290	and
O	2291	2298	Medical
O	2299	2307	Research
O	2308	2315	Council
O	2316	2325	Australia
O	2325	2326	,
O	2327	2333	Sanofi
O	2333	2334	-
O	2334	2341	Aventis
O	2341	2342	,
O	2343	2346	and
O	2347	2358	AstraZeneca
O	2358	2359	.
